Michael D.
- Country
- France
- Department
- Pulmonology
Research Overview
- Dose-Escalation Study of Zongertinib in Patients with Advanced Non-Small Cell Lung Cancer and Solid Tumors with HER2 Aberrations
- Dose-Escalation Study of Obrixtamig (BI 764532) and Ezabenlimab in DLL3-Expressing Neuroendocrine Neoplasms and Small Cell Lung Carcinoma
- Non-Inferiority Study of Pembrolizumab Maintenance Therapy at Standard vs. Reduced Dose in Metastatic Non-Squamous Lung Cancer
Data & Insights
Has run more than one trial at 296 of 548 partner sites.
Specializations
Lung Cancer Expertise
Specializes in various forms of non-small cell lung cancer (NSCLC), with particular focus on cases involving specific genetic mutations including EGFR, KRAS G12C, and ROS1 alterations.
- Advanced and metastatic NSCLC
- Targeted therapy approaches
- Early-stage disease management
Neuroendocrine Oncology
Focuses on treating neuroendocrine carcinomas including pulmonary large cell neuroendocrine carcinoma (LCNEC) and extra-pulmonary variants. Investigates novel therapeutic combinations for these rare cancers.
- Small cell lung carcinoma
- Advanced neuroendocrine tumors
- DLL3-expressing cancers
Precision Medicine
Conducts research on personalized treatment approaches using molecular targeted therapies and immunotherapy combinations. Specializes in treating tumors with specific genetic alterations.
- HER2 aberrations
- MET amplification
- RET fusion-positive cases
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.